Background: The aim of this study was to investigate the effects of chronic treatment with carvedilol in blood pressure (BPV) and heart rate (HRV) variability of rats with myocardial infarction (MI). Methods: MI was produced in male rats by ligature of anterior interventricular branch of left coronary artery. Control rats were submitted to a sham surgery (SO). MI and SO rats were randomized to receive for 30 days placebo (Plac 0.5% metilcelulose) or carvedilol (Carv, 2 mg/Kg body weight/day, drinking water): SO-Plac (N = 10), SO-Carv 
Cardiovascular diseases represent today the major cause of death and disability in the world (World Health Organization, 2008; Gaziano et al., 2010; Mittal and Singh, 2010) . Ischemic heart diseases have accounted for about 7.2 millions of deaths in 2004 (World Health Organization, 2008 . Blood pressure (BP) is one of the most important parameters to maintain cardiovascular homeostasis and its regulation depends on a complex beat-to-beat and long-term integration of efferent signals in the central nervous system to produce fine adjustments of the autonomic balance to the heart and blood vessels, thus modulating heart rate, cardiac output and peripheral vascular resistance. In pathological conditions, either afferent as well as efferent signaling may change, and thus affect BP regulation. For the better understand the hemodynamic deregulation occurring in several cardiovascular diseases, studies of patterns of blood pressure variability (BPV) have received increasing attention because it may provide sign of risk of cardiovascular death (Akselrod et al., 1985; Mancia et al., 1994; Martinka et al., 2005) and valuable information on the mechanisms of cardiovascular deregulation (Pagani et al., 1988) .
The impact of myocardial infarction (MI) on BPV has received little attention until now, mainly in experimental animals in which, unlike the studies in humans, a more detailed exploration of variables interfering in blood pressure regulation is possible (Mostarda et al., 2010) . Long-term use of beta-blockers has been strongly recommended to prevent cardiac arrhythmias and cardiac death in patients with MI (Gunnar et al., 1990) . Since adrenergic blockers interfere on the efferent sympathetic control of heart rate and vascular resistance, studies on BPV under such drugs influence are clinically relevant. Carvedilol is a non-selective beta-blocker also exhibiting alpha-1 blockade properties with increasing use in patients with MI and heart failure (Packer et al., 1996a (Packer et al., , 1996b Dargie, 2001) . However, the long-term effects of carvedilol on BPV after MI remain unknown until now. Therefore, we carried out this study to investigate the interference of chronic use of carvedilol on the spectral and temporal parameters of BPV of rats submitted to MI.
Materials and methods

Sample and myocardial infarct procedure
Fifty-one male Wistar rats of our department colony were used in the experiments. The study was approved by our institutional ethical committee (Ethics Committee in Use of Animals, protocol no. 056/11) and the experiments were conducted in accordance with the Guide for Care and Use of Laboratory Animals published by the US National Institute of Health (NIH Publication #85-23, revised 1996) . The animals (8 to 10 weeks old) were anesthetized (35 mg/kg Ketamine + 10 mg/kg Xylazine, im), the thorax was opened in the fourth left intercostal space, the heart was rapidly eviscerated and a 6-0 mononylon thread was used to produce a permanent ligature of the anterior interventricular branch of left coronary artery (N = 31), as before described (Mill et al., 1992) . Another group of rats was subjected to a sham operation (SO, N = 20), in which the coronary ligature around the coronary vessels was not tied. Twenty-four hours later, the rats were re-anesthetized with the same drugs to record a standard electrocardiogram (ECG). Presence of MI was confirmed by the presence of wide Q wave in D1 lead (Pimentel et al., 2012) . Six rats were excluded from the study because Q wave was absent, suggesting an unsuccessful coronary ligature. The MI (N = 25) and SO groups were then randomized to receive a daily treatment with carvedilol (Carv, 2 mg/Kg) or placebo (Plac, 0.5% methylcellulose vehicle) in the drinking water. The volume of water supplied was determined by the average weekly consumption in a pilot study. The rats were kept in a room with controlled temperature (20-22°C) with 12:12-h light-dark-cycle and food was provided ad libitum.
Hemodynamic evaluation of blood pressure and ECG acquisition
The treatment was discontinued one month later. The rats were then weighted, anesthetized (90 mg/Kg Ketamine + 13 mg/Kg Xylazine, ip) to insert a PE50 catheter into the left femoral artery to direct BP recording and to implant metallic electrodes under the skin to ECG recording. After 24 h, the arterial cannula was washed with saline heparinized solution (1:500 UI) and attached to a pressure transducer (TRA021, LSI, Letica, Scientific Instruments) to blood pressure monitoring (sampling rate 2 KHz). Simultaneously the metallic electrodes were connected to the input of a bioelectric amplifier (ML 132 Bio Amp) to record ECG (sampling rate 2 KHz). The pulsatile blood pressure and the ECG signals were simultaneously processed in a data acquisition system (Powerlab 4 sp, sp 4922, Adinstruments; Bridge Amp, ML 110) and analyzed in a dedicated computer with Chart 5.5.1 software. After adaption to the recording system, blood pressure and ECG were continuously recorded for 30 min. Systolic, diastolic and mean blood pressure as well as heart rate were averaged during the 30 min recording period to give basal values of these variables in the awake and unrestrained animals.
Blood pressure and heart rate variability
Time and frequency domains analyses of systolic BPV and HRV were obtained from the 30 min recording period. An algorithm was used to detect cycle-to-cycle peak systolic pressure and R waves, thus generating the beat-to-beat series of systolic pressure and R-R intervals. The series were visually inspected and artifacts and ectopic beats were manually removed (Task Force, 1996) . Time domain analysis included variance of systolic BP and variance of R-R intervals in the entire record. Frequency domain analysis was performed by autoregressive modeling with model order set in 16 (Dantas et al., 2012) . Oscillatory components were calculated by the Yule-Walker method with the Levison Durbin recursion (Souza et al., 2008) . The oscillatory components were divided in following bands: very low frequency (VLF, 0.01-0.20 Hz), low frequency (LF, 0.20-0.75 Hz) and high frequency (HF, 0.75-2.50 Hz) (Malliani et al., 1991) . Low and high frequency components were expressed also in normalized units. Normalization consisted in dividing the power of a given spectral component by the total power minus the power of VLF and multiplying the ratio by 100. LF/HF ratio was obtained by division of the components of low by high frequency, in normalized units (Malliani et al., 1991) .
Evaluation of cardiac weight and structure
After hemodynamic recording, the rats were anesthetized (90 mg/Kg Ketamine + 13 mg/Kg Xylazine, ip) and euthanatized with an intravenous injection of 3 M KCl. The thorax was opened, the heart quickly removed, washed in saline solution, dried on paper-filter, weighed (atria and ventricles), wrapped in plastic, and stored for 30 min at − 12°C. The atria were then removed and the ventricles were cut transversely into four equal segments, from the apex to the base. The sections were immersed in a 10% tripheniltetrazolium chloride solution at 37°C for 10 min, and finally immersed in 10% buffered formalin solution for 20 min. This procedure allowed increasing the contrast between the intact myocardial and the infarct scar. Images of sections were scanned (Scanjet 2400) and analyzed by planimetry with a software (Image J 1.40 g). Infarct size, expressed as percentage, was calculated by dividing the sum of infarct areas from all sections by the sum of left ventricle areas from all sections (including those without infarct scar) and multiplying by 100 (Takagawa et al., 2007) . Relative heart weight was calculated dividing heart weight by body weight.
Statistical analyses
Normality of data was evaluated by Shapiro-Wilk test and variance homogeneity by Levene test. MI size was compared with twotail unpaired t-test. Body weight, relative cardiac weight, heart rate, BPV and HRV variables, were ranked before comparisons. These variables, and the hemodynamic parameters (systolic, diastolic, and mean blood pressures), body weight and cardiac weight were compared by two-way ANOVA followed by the Bonferroni post hoc test for multiple comparisons. Only the following comparisons between groups were tested in the post-hoc test: SO-Plac vs. SO-Carv (to test the effect of the Carv), SO-Plac vs. MI-Plac (to test the effect of the infarct) and MI-Plac vs. MI-Carv (to test the effect of Carv in presence of MI). Statistical significance was set in P b 0.05 and SPSS 15.0 was used to perform all analyses. Unless otherwise stated, data are expressed as mean ± standard deviation.
Results
Body weight before surgery was similar in the four groups (SO-Plac = 245 ± 12 g; SO-Carv = 250 ± 7 g; MI-Plac = 238 ± 9 g; MI-Carv = 223 ± 5 g; P > 0.05; two-way ANOVA). The body weight gain during the treatment period was similar in the four groups, so that the final body weight was also similar in the four groups at the end of the study (SO-Plac = 376 ± 19 g; SO-Carv = 384 ± 7 g; MI-Plac = 362 ± 11 g; MI-Carv = 328 ± 7 g; P > 0.05; two-way ANOVA).
Cardiac structure
No visible scar was observed in rats submitted to sham surgery, while a remarkable transmural scar was observed in all animals submitted to coronary ligature. The infarct size was unaffected by carvedilol treatment (MI-Plac = 33 ± 7 % vs. MI-Carv = 37 ± 12%; P > 0.05). Fig. 1 shows the absolute and relative weight of the heart in the four groups. A significant increase of the cardiac weight was observed in the untreated infarcted group, which was fully prevented by carvedilol treatment.
Hemodynamic data
The hemodynamic data recorded in the awake and unrestrained rats one month after coronary ligature or sham surgery are shown in Table 1 . Data have shown that the infarcted rats were hemodynamically stabilized since BP and heart rate values were like non-infarcted animals. No significant differences was found between groups, although a slight tendency to reduced BP and heart rate values were observed in infarcted group treated with carvedilol.
BPV analyses
A notable decrease in several components of time and frequency domains of BPV was observed in rats with healed infarction (Table 2 ). The only parameter without significant reduction was the HF component (absolute units), which is more dependent on oscillation of venous return due to respiratory movements. Nevertheless, when this same spectral component was evaluated in normalized units, significant differences were observed in infarcted rats. Carvedilol given to sham-operated animals did not produce significant changes in none of the parameters analyzed. However, carvedilol treatment prevented changes in BPV after infarction. Spectral indexes of BPV also tended to increase after chronic carvedilol treatment, but without statistical significance. Noteworthy, there was a significant change in the proportion of LF and HF normalized values after infarction, with a remarkable decrease of LF component and an increase of HF component in infarcted as comparison with non-infarcted rats.
HRV analyses
Absolute indexes of HRV were not significantly altered by MI (Table 3) . Nevertheless, a tendency to reduction in parasympathetic modulation (observed by a non-significant decrease of normalized HF) was seen in infarcted animals. Conversely, treatment with carvedilol tended to increase all HRV variables and to restore the values of the normalized HF component.
Discussion
Our study assessed the effect of chronic treatment with carvedilol on BPV in rats underwent MI. Previous studies (Detollenaere et al., 1993; Kardos et al., 1996; Mostarda et al., 2010) evaluated BPV in MI, but to our knowledge, this was the first study that investigated the effect of long-term treatment with carvedilol on BPV in an experimental infarction model.
It is known that HF component of HRV is a marker of vagal modulation of heart beats (Task Force, 1996) , while the HF power of BPV reflects oscillations of pressure caused by respiratory movements, involving also fluctuations of the cardiac output of purely mechanical origin (Julien et al., 1995) . Some authors have argued that the LF band can be considered as a marker of sympathetic activity driven to sinoatrial node and peripheral vasculature (Pagani et al., 1988; Parati et al., 1995) . Others have shown that this HRV component is influenced by both sympathetic and parasympathetic components of the autonomic nervous system (Pomeranz et al., 1985) , according to data obtained with pharmacological manipulation of the autonomic nervous system. In the present study, 30 days after MI or sham Values are median and interquartile range (p75-25). SO-Plac -Sham operated placebo; SO-Carv -Sham Operated Carvedilol; MI-Plac -myocardial infarction placebo; MI-Carv -myocardial infarction carvedilol; SBP -systolic blood pressure; MBPmean blood pressure; DBP -diastolic blood pressure; HR -heart rate. No significant differences were found. All data were compared by two-way ANOVA. HR was ranked before comparisons. surgery the HRV analysis has shown similar values between infarcted and non-infarcted rats and treatment with carvedilol seems has not affected the results. Acute carvedilol administration to awake rats produces intense bradicardia and depression of LF component of HRV (Bertera et al., 2012) . However, a fast liver metabolization occurs so that normal heart rate values are recovered after 90 min. In our study, carvedilol treatment was interrupted 24 h before blood pressure recording. Therefore, it is likely that our data are related to chronic adaptations to carvedilol treatment and do not represent acute effects of the drug. However, according to previous studies, an increase sympathetic drive directed to the heart and blood pressure would be expected in untreated infarcted rats. Changes in sympathetic drive, however are depends on time course of heart failure development. A transient tachycardia is observed in the acute infarct phase that resumes during infarct healing (Francis et al., 2001 ). In our study, animals were investigated in a compensated phase of infarction exhibiting normal values of heart rate in basal conditions. Therefore, even in presence of infarction, a normal autonomic balance directed to heart seems to be present in the studied animals. It is possible that larger infarcts than those used in the present study would produce different results in relate to basal hemodynamic values and HRV.
Few experimental studies have investigated changes of BPV after MI. One of them (Mostarda et al., 2010) evaluated the spectral indexes of BPV three months after coronary ligature, and an important increase of the LF component (measured in absolute units) was observed, without any change in the HF component. Our study showed an overall decrease of BPV in the rats with healed MI, a finding partially prevented in the infarcted group submitted to the chronic use of carvedilol. Our data agreed with a previous study (Kardos et al., 1996) that also found decreased BPV in patients 3-5 days after infarction. BPV is linked to beat-to-beat changes in stroke volume. Thus, these authors hypothesized that the BPV attenuation could be related to a relative invariance of stroke volume caused by a reduced left ventricular compliance. In our results, we observed decreased values of the systolic pressure variance and LF component (absolute and normalized) and an increase of the normalized HF. However, BPV changes seen in the present study are in accordance with pathophysiological alterations reported in literature ( Van de Borne et al., 1997; Notarius et al., 1999; Ohte et al., 2012) . The LF component coincides with the slow blood pressure waves (Mayer's waves) is a marker to the vascular sympathetic activity modulated by baroceptor reflex, and its increase is expected in diseases that coursing with increases of the sympathetic efference. However, the LF rise does not occur always, and its increment or decrement seems be depend of the amplitude of sympathetic modulation, which is closely related to time course and severity of a disease, such as occurs in acute stages of MI until chronic stages of the heart failure. Thus, previous studies (Guzzetti et al., 1995; Van de Borne et al., 1997; Notarius et al., 1999; Ohte et al., 2012) have shown that in moderated-to-severe heart failure, chronic high catecholamine levels produced by chronic sympathetic discharge may produce uncoupling of adrenergic receptors (possibly by down-regulation) thus decreasing the power of LF oscillatory component, or still that the loss of central rhythmical modulation of sympathetic discharge to the periphery. This explains the strange paradox of sympathetic excess activity and the fall of LF BPV (and HRV) component in presence of chronic heart failure. Moreover, it was reported in clinical and experimental studies (Kruger et al., 1997; La Rovere et al., 1998 ) that sympathetic vasomotor baroreflex sensitivity decreases after MI. Interestingly, conversely of reported on experimental studies in sino-aortic denervation (Di Rienzo et al., 1991; Rodrigues et al., 2011) , the variance of blood pressure had shown a notable decreasing after myocardial infarction. Although a great increase in blood pressure variance was expected due to withdrawal of baroceptor activity, which could be a mechanism to attenuate high blood pressure changes, the data of our study appear to counter this hypothesis. Rats submitted to MI had a marked reduction on BPV. These results are in accordance with short or long-term observations in subjects with heart failure, in which BPV is also decreased (Caruana et al., 1988; Guzzetti et al., 1995; Giles et al., 2001 ). Our results also had shown a significant increase of normalized HF BPV component. It was reported that hypoxemia in presence of heart failure or the reduced perfusion of aortic and carotid bodies may produce hyperexcitation of chemicalreceptors and sympathetic activation even in presence of decreased baroreflex sensitivity (Kara et al., 2003) . Once this component is highly affected by respiration, it is likely that increase of peripheral chemical-receptors discharges may account for the increment of HF values.
In clinical context, the effect of carvedilol treatment was previously evaluated (Piccirillo et al., 2000) on HRV and BPV in subjects with heart failure. However, the identification of carvedilol effects in clinical setting is difficult to evaluate, since beta-blockers are usually used in combination with other drugs in patients with heart failure. In this work (Piccirillo et al., 2000) , for example, patients were also under the effects of other drugs, such as digoxin, enalapril, and furosemid. The digoxin shows direct effect on vascular smooth muscle, while enalapril blocks the synthesis of angiotensin-II. Therefore, both treatments are able to interfere in the BPV, mainly in the LF component, and thus, in the peripheral vascular tone. The carvedilol treatment improve the HRV, increasing the total power of spectrum and absolute (LF and HF) and HF normalized components, decreasing the LF normalized and the LF/HF ratio, suggesting a reduction in the sympathetic modulation simultaneously to an increased vagal modulation directed to the heart. With regard to BPV, it was observed a decreasing in the LF normalized, that the authors attributed to effect of reduction in sympathetic modulation to the vessels due adrenergicblocker effect of carvedilol on α-1 receptors, and an increasing of normalized HF. These data, nevertheless, are of restricted comparability to the studies with experimental animals. In the present study, the carvedilol treatment was started in acute stage of MI, before chronic heart failure development. Moreover, the carvedilol was tested as only drug in animals with and without MI. Other studies (Mortara et al., 2000; Bullinga et al., 2005 ) also reported benefit of carvedilol treatment on HRV, showing increasing of vagal modulation, decreasing in sympathetic modulation and increasing the total power of spectrum.
The increasing of cardiac weight constitutes an important marker of cardiac remodeling in infarcted heart, and this fact occurred in infarcted rats without treatment. Carvedilol treatment prevented the weight increasing. This result agreed with a previous study (Watanabe et al., 2000) that has shown increasing of cardiac weight in rats with heart failure, and normal cardiac weight when the rats were treated with carvedilol. Finally, some limitations need to be considered. First, infarction and heart failure are evolving process. Therefore, longitudinal observations of hemodynamic parameters should provide better information about the efficacy of pharmacological treatments to maintain physiological variables under normal values despite the harm to mechanical performance of infarcted hearts. However, assessment of BPV needs precise measurement of systolic blood pressure. Thus, invasive BP recording techniques are mandatory in such conditions. Our data, therefore, were related only to rats surviving to infarction and nearly 50% of the rats died after coronary ligature. Mortality, however, was similar in rats treated or untreated with carvedilol. Therefore, we cannot rule out the possibility that effects produced by beta-blockade occurred only in the sub-group of animals with better survival after coronary ligature. Moreover, our evaluations were focused in methods of power spectral analyses, and thus, more two issues should be communicated. First, we did not use a specific test to assess the stationarity of the analyzed series. The stationarity hypothesis was assumed because short length frames were used in the analyses. However, it has been shown (Magagnin et al., 2011 ) that non-stationarities are frequently present even in well-controlled experiments, which potentially might biasing the spectral indices. In this context, our goal is implement a stationarity test to analyses in next works. Second, it have been reported that loss of discriminative power of spectral analysis can occur in some pathological conditions because rhythms with unstable frequencies might escape outside the assigned and fixed limits of frequency bands or by the presence of non linear components that producing harmonics which escaping the band limits, thus being unaccounted by spectral analysis (Tobaldini et al., 2009b) . Therefore, some authors (Tobaldini et al., 2009a (Tobaldini et al., , 2009b have shown that symbolic analysis, a non-linear method of analysis of cardiovascular variability, could be used to solve this problem, once that it quantifies sympathetic and vagal modulation without determine limits of the frequency bands. Nevertheless, as our main objective was to perform an overall investigation of the cardiovascular variability, including BPV evaluations by spectral analysis, we believe which the methods of data analysis here used were also pertinently relevant.
Conclusion
In brief, BPV was impaired in hemodynamically stable rats with chronic MI. Carvedilol treatment partially prevented the BPV decrease. Moreover, carvedilol also prevented the well-known cardiac hypertrophy after infarction. The results of this study provide evidences of the benefit and security of chronic use of carvedilol after MI.
